From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Interview with Michelle Kirschner RN, MSN, ACNP, APRN-BC: Use of the Breast Cancer Index in Guiding Extended Endocrine Therapy

View all
FROM THE EDITORS

Welcome to the HR+ HER2– Breast Cancer Resource Center! We are pleased to offer a curated selection of current information, practice advancements, literature highlights, and professional resources focused on this clinical area. Our goal is to support advanced practitioners in their critical role of providing evidence-based, high-quality care to patients.

For any questions, comments, suggestions or to request information on a specific topic, please contact us at jadpro-editor@conexiant.com.

 

 

Katie Newlin, RN, MSN, AGPCNP-BC

Washington University in St. Louis/Siteman Cancer Center

 

Lisa Salem, MSN, FNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

Resources

Clinical Characteristics and Treatment Persistence in US Patients with HR+/HER2-, Node Positive Early Breast Cancer Treated with Abemaciclib: Real-World Study from First Year After Approval

HER2 Testing in Breast Cancer - 2023 Guideline Update

Exploring the Treatment Gap in High-Risk HR+, HER2- Early Breast Cancer (EBC): Eligible Patients Not Receiving Abemaciclib in the US

Ribociclib Plus Endocrine Therapy in Early Breast Cancer

Abemaciclib AE Monitoring

News & Literature Highlights

American Medical Journal

Updates in advanced hormone receptor-positive breast cancer: From circulating tumor DNA-guided therapy to precision medicine

Journal of Clinical Oncology

Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study

Science Progress

Advancements in non-invasive biomarkers for detection and monitoring of breast cancer recurrence

Journal of Clinical Oncology

Single center study of efficacy and safety of capivasertib in hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC)

Annals of Medicine

Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A systematic review and meta-analysis

Journal of Clinical Oncology

Development and validation of the RSClinN+ tool to predict prognosis and chemotherapy benefit for hormone receptor–positive, node-positive breast cancer

Journal of Clinical Oncology

Development and validation of a model to predict future breast cancer risk after ER-positive and HER2-negative breast cancer

Annals of Oncology

Overall survival with abemaciclib in early breast cancer

JAMA Oncology

Breast cancer index in premenopausal women with early-stage hormone receptor–positive breast cancer

Frontiers in Oncology

Cryoablation in the treatment of early breast cancer: A comprehensive analysis

Advertisement
Case Studies

Navigating Treatment Adherence in Early-Stage Breast Cancer

Isolated Brain Metastasis in BRCA2-Mutated HR+ HER2- Breast Cancer

Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer

Advertisement
Quizzes
Test your knowledge of treatment adherence in early-stage breast cancer
Test your knowledge of isolated brain metastasis in BRCA2-mutated HR+ HER2- breast cancer
Test your knowledge of genetic testing and risk intervention based on family history of early-onset breast cancer